Bintabara Deogratius, Hyera Sola T, Shayo Festo K
Department of Community Medicine, School of Medicine and Dentistry, The University of Dodoma, Dodoma, Tanzania.
Department of Internal Medicine, School of Medicine and Dentistry, The University of Dodoma, Dodoma, Tanzania.
BMC Endocr Disord. 2025 Aug 18;25(1):196. doi: 10.1186/s12902-025-01968-3.
Metabolic syndrome (MetS) is becoming prevalent among People living with HIV (PLWHIV), attributed to antiretroviral therapy, HIV infection and other concomitant factors. A high burden of HIV/AIDs and Non-communicable diseases in Sub-Saharan Africa calls for an extra focus on the MetS among people living with HIV. The study aimed at assessing the factors associated with MetS among PLWHIV on the first-line antiretroviral therapy.
This was a cross-sectional design whereby a convenience sampling technique was used to recruit a sample of 255 participants. The interview-guided questionnaire was used to obtain relevant information from the study participants as well as to record physical measurements (Blood pressure, weight, height and body mass index) and biochemical profiles (fasting blood glucose, lipid profile, CD4 count, and Hemoglobin level). MetS was established by using the Adult Treatment Panel III criteria. Descriptive statistics and binary logistic regression were used to analyze the data, and all statistical analyses were performed using Stata version 17.0. A P value less than 0.05 was considered for statistical significance.
The mean age and BMI were 46 ± 2 years and 25.0 ± 5.3 kg/m, respectively. The majority 161 (63.1%) of participants were females and 29 (11.4%) were either current smokers or former smokers. The prevalence of MetS was 21.2% and the factors associated with metabolic syndrome were age > 45 years (AOR = 10.483, 95% CI = 1.336-82.231), being obese (AOR = 11.39, 95% CI = 2.23-58.32), currently smoking (AOR = 3.97, 95% CI = 1.10-14.34) and being single (AOR = 2.84, 95% CI = 1.11-7.26).
The prevalence of MetS in this study was relatively high among PLWHIV on first-line ART. Age above 45 years, being single, current smoking, and obesity were independent predictors of MetS. Regular monitoring for clinical and laboratory parameters, surveillance of drug effects and behavioral interventions are needed to optimize the management and prevention of metabolic disorders in PLWHIV.
Not applicable.
代谢综合征（MetS）在人类免疫缺陷病毒感染者（PLWHIV）中日益普遍，这归因于抗逆转录病毒疗法、HIV感染及其他相关因素。撒哈拉以南非洲地区HIV/AIDS和非传染性疾病的高负担情况，要求特别关注HIV感染者中的代谢综合征。本研究旨在评估接受一线抗逆转录病毒治疗的PLWHIV中与MetS相关的因素。
这是一项横断面设计，采用便利抽样技术招募了255名参与者。使用访谈式问卷从研究参与者那里获取相关信息，并记录身体测量数据（血压、体重、身高和体重指数）以及生化指标（空腹血糖、血脂谱、CD4计数和血红蛋白水平）。采用成人治疗小组III标准来确定MetS。使用描述性统计和二元逻辑回归分析数据，所有统计分析均使用Stata 17.0版本进行。P值小于0.05被视为具有统计学意义。
参与者的平均年龄和BMI分别为46±2岁和25.0±5.3kg/m²。大多数参与者161名（63.1%）为女性，29名（11.4%）为当前吸烟者或既往吸烟者。MetS的患病率为21.2%，与代谢综合征相关的因素有年龄>45岁（调整后比值比[AOR]=10.483，95%置信区间[CI]=1.336 - 82.231）、肥胖（AOR=11.39，95%CI=2.23 - 58.32）、当前吸烟（AOR=3.97，95%CI=1.10 - 14.34）和单身（AOR=2.84，95%CI=1.11 - 7.26）。
本研究中接受一线抗逆转录病毒治疗的PLWHIV中MetS的患病率相对较高。45岁以上、单身、当前吸烟和肥胖是MetS的独立预测因素。需要定期监测临床和实验室参数、药物效果监测以及行为干预，以优化PLWHIV中代谢紊乱的管理和预防。
不适用。
